NASDAQ · OKUR
OnKure Therapeutics, Inc.
$2.62-$0.01 (-0.38%)
OnKure Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.3% below the high.
Loading market information…
NASDAQ · XLO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Xilio Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Xilio Therapeutics, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.94. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Xilio Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$2.52-2,190.91% vs estimate | $2.92M-33.75% vs estimate |
|---|
| Q4 2024 | Mar 11, 2025 | -$2.80+9.09% vs estimate | $1.72M-47.76% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$3.08+12.0% vs estimate | $2.28M-30.91% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $16.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.62-$0.01 (-0.38%)
OnKure Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.3% below the high.
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$7.29$0.00 (0.0%)
Kezar Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.44% below the high.
$1.53+$0.15 (+10.87%)
Actinium Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
$1.74-$0.07 (-3.87%)
LAVA Therapeutics N.V.’s quoted price sits in the upper half of its reported 52-week range, 13.0% below the high.
$9.07-$0.15 (-1.63%)
FibroGen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.68% below the high.
$5.03-$0.14 (-2.71%)
Aligos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
